A clinical trial update dated August 28, 2026 shows a new Phase 3 study of ecnoglutide, also known as XW003, is now recruiting participants. The trial, registered as NCT07434050, is titled "A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy." According to the listing, the study targets obese individuals diagnosed with obstructive sleep apnea who are already receiving positive airway pressure therapy. The trial's current status is listed as recruiting, indicating that enrollment of eligible participants is underway as of the update date.
Ecnoglutide remains classified as an unapproved compound under research investigation. No outcome data, efficacy results, or safety findings have been reported as part of this update. The listing reflects only the trial's registration status, phase designation, and recruitment stage at this time.
This Phase 3 designation indicates the study is in a later stage of clinical development compared to earlier phase trials, though no results have been posted. Readers interested in this compound can consult the trial registry directly for eligibility criteria and further details as the study progresses. For more background on ecnoglutide, see the compound overview.